A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
Latest Information Update: 26 Jun 2023
At a glance
- Drugs SOR C13 (Primary)
- Indications Carcinoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 22 Jun 2023 Status changed from recruiting to completed.
- 20 Oct 2022 Planned End Date changed from 9 Aug 2022 to 9 Aug 2023.
- 20 Oct 2022 Planned primary completion date changed from 9 Aug 2022 to 9 Aug 2023.